Cargando…

Experimental Drugs for the Treatment of Hepatitis D

Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until condition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandmann, Lisa, Cornberg, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057838/ https://www.ncbi.nlm.nih.gov/pubmed/33889032 http://dx.doi.org/10.2147/JEP.S235550

Ejemplares similares

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
por: Lampertico, Pietro, et al.
Publicado: (2023)

Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
por: Wranke, Anika, et al.
Publicado: (2023)

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience
por: Sandmann, Lisa, et al.
Publicado: (2021)

Barriers of hepatitis C virus interspecies transmission
por: Sandmann, Lisa, et al.
Publicado: (2013)

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review
por: Sperle, Ida, et al.
Publicado: (2020)

The role of HBsAg levels in the current management of chronic HBV infection
por: Höner zu Siederdissen, Christoph, et al.
Publicado: (2014)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Novel Experimental Drugs for Treatment of Multiple Myeloma
por: Offidani, Massimo, et al.
Publicado: (2021)

Experimental Viral Hepatitis
por: Mc Collum, Robert W.
Publicado: (1969)

Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy
por: Ravens, Sarina, et al.
Publicado: (2018)

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
por: Dibba, Pratima, et al.
Publicado: (2018)

A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B
por: Lampertico, Pietro, et al.
Publicado: (2018)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry
por: Hinrichsen, Holger, et al.
Publicado: (2020)

Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients
por: Cornberg, Markus, et al.
Publicado: (2021)

An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome
por: Deleeuw, Violette, et al.
Publicado: (2021)

Antioxidant Protection from UV- and Light-Stress Related to Carotenoid Structures
por: Sandmann, Gerhard
Publicado: (2019)

Carotenoids and Their Biosynthesis in Fungi
por: Sandmann, Gerhard
Publicado: (2022)

Genes and Pathway Reactions Related to Carotenoid Biosynthesis in Purple Bacteria
por: Sandmann, Gerhard
Publicado: (2023)

Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen
por: Cornberg, Markus, et al.
Publicado: (2023)

Web-Based Information Infrastructure Increases the Interrater Reliability of Medical Coders: Quasi-Experimental Study
por: Varghese, Julian, et al.
Publicado: (2018)

Endpoints and New Options for Treatment of Chronic Hepatitis D
por: Lok, Anna S., et al.
Publicado: (2021)

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
por: Bishara, Delia, et al.
Publicado: (2020)

Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients
por: Gömer, André, et al.
Publicado: (2023)

Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review
por: Mravčík, Viktor, et al.
Publicado: (2013)

Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy
por: Ooka, Kohtaro, et al.
Publicado: (2016)

Drug Delivery Strategies for Antivirals against Hepatitis B Virus
por: Singh, Latavia, et al.
Publicado: (2018)

Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity
por: Strunz, Benedikt, et al.
Publicado: (2018)

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)
por: Cornberg, Markus, et al.
Publicado: (2022)

Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
por: Maasoumy, Benjamin, et al.
Publicado: (2013)

Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy
por: Schulte, Benjamin, et al.
Publicado: (2020)

Generation of stable homozygous transformants of diploid yeasts such as Xanthophyllomyces dendrorhous
por: Sandmann, Gerhard
Publicado: (2022)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
por: Soriano, Vicente, et al.
Publicado: (2023)

Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C
por: Khera, Tanvi, et al.
Publicado: (2021)

Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
por: Kuo, Meng-Hsuan, et al.
Publicado: (2020)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
por: Boettler, Tobias, et al.
Publicado: (2020)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry
por: Tacke, Frank, et al.
Publicado: (2022)

Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model
por: Martínez Soriano, Blanca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_722voko3e33kk5mat12ucs19ak